Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: Implementation in the NHS

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 122, Issue 12, 2015, Pages 1682-1686

  Soothill, P W ^a   Finning, K ^b   Latham, T ^b   Wreford Bush, T ^c   Ford, J ^a   Daniels, G ^b  

^a ST MICHAEL'S HOSPITAL   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Anti D; cffDNA; non invasive prenatal testing; RhD; RHD; rhesus disease

Indexed keywords

CELL FREE FETAL DNA; DNA; RHESUS D ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; BLOOD GROUP RHESUS SYSTEM; IMMUNOLOGIC FACTOR;

ARTICLE; CELL FREE FETAL DNA TESTING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; FEMALE; HEALTH CARE POLICY; HUMAN; MATERNAL CARE; MATERNAL SERUM SCREENING TEST; MEDICAL SERVICE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHESUS INCOMPATIBILITY; UMBILICAL CORD BLOOD; ADULT; ANEMIA, HEMOLYTIC; BLOOD; BLOOD GROUP RHESUS SYSTEM; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PREGNANCY; RHESUS ISOIMMUNIZATION;

ADMINISTRATION, INTRAVENOUS; ADULT; ANEMIA, HEMOLYTIC; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH POLICY; HUMANS; IMMUNOLOGIC FACTORS; ISOANTIBODIES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PROSPECTIVE STUDIES; RH ISOIMMUNIZATION; RH-HR BLOOD-GROUP SYSTEM; STATE MEDICINE;

EID: 84945299714     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13055     Document Type: Article

References (10)

1. Hadley A, Soothill PW,. Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn. Cambridge, UK: Cambridge University Press, 2005. ISBN: 9780521018043.
2. NICE. Routine antenatal anti-D prophylaxis for women who are rhesus D negative. Technology appraisal guidance 156. 2008. [ www.nice.org.uk/guidance/ta156 ]. Accessed 7 August 2014.
3. Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al., Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-8.
4. Finning KM, Martin PG, Soothill PW, Avent ND,. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42: 1079-85.
5. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G,. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336: 816-18.
6. Chitty LS, Finning K, Massey E, Soothill P, Daniels G,. Antenatal determination of fetal rhesus status using free fetal DNA in the maternal circulation before 20 weeks' gestation: is routine application practical and beneficial? Arch Dis Child Fetal Neonatal Ed 2011; 96 (Suppl 1): Fa1-16.
7. Kent J, Farrell AM, Soothill P,. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth 2014; 14: 87.
8. Clausen FB, Christiansen M, Steffensen R, Jørgensen S, Nielsen C, Jakobsen MA, et al., Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52: 752-8.
9. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M,. Noninvasive single- exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120: 227-34.
10. de Haas M, van der Ploeg CPB, Scheffer PG, Verlinden DA, Hirschberg H, Abbink F, et al., A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D. ISBT Sci Ser 2012; 7: 164-7.